Gaddis Premier Wealth Advisors LLC Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Posted by Brian Himes on Jun 9th, 2026

Gaddis Premier Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,165 shares of the medical research company’s stock, valued at approximately $1,255,000. Thermo Fisher Scientific makes up 1.0% of Gaddis Premier Wealth Advisors LLC’s investment portfolio, making the stock its 20th biggest holding.

Other institutional investors also recently bought and sold shares of the company. Assetmark Inc. lifted its position in shares of Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares in the last quarter. Cornerstone Investment Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $41,393,000. Mackenzie Financial Corp lifted its position in shares of Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after acquiring an additional 62,790 shares in the last quarter. NEOS Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 28.6% in the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after acquiring an additional 11,415 shares in the last quarter. Finally, Factory Mutual Insurance Co. lifted its position in shares of Thermo Fisher Scientific by 2.6% in the third quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock valued at $47,985,000 after acquiring an additional 2,500 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the topic of several recent research reports. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. DZ Bank initiated coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective on the stock. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $613.67.

Check Out Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $469.41 on Tuesday. The business’s 50-day moving average price is $479.56 and its 200 day moving average price is $530.08. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99. The company has a market capitalization of $174.44 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the business posted $5.15 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.